PLX Protalix BioTherapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Protalix BioTherapeutics, Inc. (PLX) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 18, 2026, a 10-Q quarterly report filed on May 13, 2026, an 8-K current report filed on June 25, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Protalix BioTherapeutics, Inc. (PLX) (SEC CIK 1006281), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Protalix BioTherapeutics, Inc.
Ask AI about PLX filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting PLX positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on PLX.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Protalix BioTherapeutics, Inc. (PLX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jun 25, 2026 | - | - | - |
8-K | May 21, 2026 | - | - | |
8-K | May 13, 2026 | - | - | |
10-Q | May 13, 2026 | Mar 31, 2026 | - | |
10-K | Mar 18, 2026 | Dec 31, 2025 | - | |
8-K | Mar 18, 2026 | - | Analysis | - |
8-K | Mar 9, 2026 | - | Analysis | - |
8-K | Feb 11, 2026 | - | - | |
8-K | Jan 30, 2026 | - | - | |
8-K | Jan 5, 2026 | - | - | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 14, 2025 | Jun 30, 2025 | - | |
10-Q | May 9, 2025 | Mar 31, 2025 | - | |
10-K | Mar 17, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 14, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 14, 2024 | Jun 30, 2024 | - | |
10-Q | May 10, 2024 | Mar 31, 2024 | - | |
10-K | Mar 14, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | - | |
10-Q | May 4, 2023 | Mar 31, 2023 | - | |
10-K | Feb 27, 2023 | Dec 31, 2022 | - | |
10-Q | Nov 14, 2022 | Sep 30, 2022 | - | |
10-Q | Aug 15, 2022 | Jun 30, 2022 | - | |
SC 13G | Jun 9, 2022 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate PLX share value held by 13F filers tracked by SignalX, by quarter.
- State Street Corp+387.6K (+66%)
- Dimensional Fund Advisors+268.1K (+933%)
- Morgan Stanley+169.8K (+129%)
- Bank of America Corp+32.7K (+71%)
- Northern Trust+19.7K (+2%)
- Citadel Advisors LLC292.6K (-81%)
- Wells Fargo & Co52.5K (-66%)
- Renaissance Technologies LLC38.5K (-3%)
- BlackRock30.1K (-1%)
- Goldman Sachs Group11.5K (-4%)
- AQR Capital Management+30.5K
- Two Sigma Investments+18.1K
- Prudential Financial+10.1K
- Vanguard Group Inc−488.6K
- Invesco Ltd−50.6K
- JPMorgan Chase & Co−30.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 95 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest PLX SEC filings in 2026?
Protalix BioTherapeutics, Inc. (PLX) has filed a 10-K annual report on March 18, 2026, a 10-Q quarterly report on May 13, 2026, an 8-K current report on June 25, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PLX file its most recent 10-K annual report?
Protalix BioTherapeutics, Inc. (PLX) filed its most recent 10-K annual report on March 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PLX 10-Q quarterly reports?
Protalix BioTherapeutics, Inc. (PLX)'s most recent 10-Q quarterly report was filed on May 13, 2026. SignalX displays every PLX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PLX filed recently?
Protalix BioTherapeutics, Inc. (PLX)'s most recent 8-K was filed on June 25, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PLX insider trading activity (Form 4)?
SignalX aggregates every PLX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PLX file with the SEC?
Protalix BioTherapeutics, Inc. (PLX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PLX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Protalix BioTherapeutics, Inc. (PLX).
What is PLX's SEC CIK number?
Protalix BioTherapeutics, Inc. (PLX)'s SEC CIK (Central Index Key) number is 1006281. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1006281 to look up all PLX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Protalix BioTherapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 125+ filings.